natgillin/translations-raw huggingface dataset:
There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day).
104 tedne v odmerkih do 77 mg/kg na dan (kar predstavlja najmanj 25-krat višjo izpostavljenost kot pri človeku ob prejemanju kliničnega odmerka 75 mg/dan).
- efavirenz, a medicine to treat HIV (human immunodeficiency virus) infections,
- flukonazol ali vorikonazol, zdravila za zdravljenje glivičnih okužb,
Contents of the pack and other information What Clopidogrel ratiopharm GmbH contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Klopidogrel ratiopharm GmbH
Mean peak plasma levels of unchanged clopidogrel (approximately 2.2 - 2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing.
2,2-2,5 ng/ml po enem 75-mg peroralnem odmerku) se je pojavila približno 45 minut po odmerjanju.
How to store Clopidogrel ratiopharm GmbH Contents of the pack and other information
Shranjevanje zdravila Klopidogrel ratiopharm GmbH Vsebina pakiranja in dodatne informacije
Clopidogrel ratiopharm GmbH with food and drink
Zdravilo Klopidogrel ratiopharm GmbH skupaj s hrano in pijačo
You have been prescribed Clopidogrel ratiopharm GmbH to help prevent blood clots and reduce the risk of these severe events because:
Zdravilo Klopidogrel ratiopharm GmbH vam je predpisano za pomoč pri preprečevanju nastajanja krvnih strdkov in za zmanjšanje tveganja teh hudih dogodkov, ker: - imate stanje otrdelih arterij (znano tudi kot ateroskleroza), in
-Common side effects (may affect up to 1 in 10 people): Diarrhoea, abdominal pain, indigestion or heartburn.
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov): driska, bolečina v trebuhu, slaba prebava ali zgaga.
43 patients (13.4%) in the de-escalated DAPT group and in 85 patients (26.3%) in the unchanged DAPT group (p<0.01).
30 bolnikih (9,3 %) v skupini z deeskaliranim DAPT in pri 76 bolnikih (23,5 %) v skupini z nespremenjenim DAPT (p < 0,01).
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1752) or placebo (n=1,739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin.
Bolniki so dobivali klopidogrel (300 mg udarni odmerek, nato pa 75 mg na dan, n=1.752) ali placebo (n=1.739), oboje v kombinaciji z ASA (150 mg do 325 mg kot udarni odmerek, nato 75 mg do 162 mg na dan),
Other medicines and Clopidogrel ratiopharm GmbH
Druga zdravila in zdravilo Klopidogrel ratiopharm GmbH
You have a condition of hardening of arteries (also known as atherosclerosis), and You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease (disturbed blood flow in arms or legs caused by vascular occlusions) or
- ste predhodno doživeli srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska bolezen (moten krvni pretok v rokah ali nogah, ki ga povzroči zapora žil) ali - ste doživeli hudo obliko bolečine v prsih, znano kot “nestabilna angina” ali “miokardni infarkt” (srčni napad).
signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Warnings and precautions').
To so lahko znaki redkega zmanjšanja števila določenih krvnih celic, - znaki jetrnih težav, kot je porumenelost kože in/ali oči (zlatenica), ki so lahko, ali pa ne, povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo
Patients were randomized to receive either prasugrel 5 or 10 mg/d (Days 0-14) (n=1309), or prasugrel 5 or 10 mg/d (Days 0-7) then de-escalated to clopidogrel 75 mg/d (Days 8-14) (n=1309), in combination with ASA (<100 mg/day).
(od 0. do 14. dne) (n = 1309) bodisi na prejemanje prasugrela 5 ali 10 mg/dan (od 0. do 7. dne) s poznejšim deeskaliranjem na 75 mg klopidogrela na dan (od 8. do 14. dne) (n = 1309) v kombinaciji z ASA (< 100 mg/dan).
(alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician.
Bolniki morajo biti obveščeni, da je lahko čas, potreben za zaustavitev krvavitve, daljši kot ponavadi, ko jemljejo klopidogrel (sam ali v kombinaciji z ASA) in da morajo poročati svojemu zdravniku o kakršni koli neobičajni krvavitvi (mesto ali trajanje).
If you forget to take Clopidogrel ratiopharm GmbH
Če ste pozabili vzeti zdravilo Klopidogrel ratiopharm GmbH
While you are taking Clopidogrel ratiopharm GmbH:
Ko jemljete zdravilo Klopidogrel ratiopharm GmbH:
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs), or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5).
heparinom, zaviralci glikoproteina IIb/IIIa ali nesteroidnimi protivnetnimi zdravili (NSAIDs) vključno z zaviralci COX-2, ali s selektivnimi zaviralci privzema serotonina (SSRI) ali z drugimi zdravili, ki so povezana s tveganjem za krvavitve, kot je pentoksifilin (glejte poglavje 4.5).
What Clopidogrel ratiopharm GmbH looks like and contents of the pack
Izgled zdravila Klopidogrel ratiopharm GmbH in vsebina pakiranja
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG).
Delež bolnikov s primarnim opazovanim dogodkom [srčno-žilna (SŽ) smrt, miokardni infarkt (MI) ali kap] je bil 582 (9,3 %) v skupini, zdravljeni s klopidogrelom, in 719 (11,4 %) v skupini, ki je prejemala placebo, to je 20 % zmanjšanje relativnega tveganja (95 % IZ od 10 % - 28 %; p=0,00009)
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 ‘Possible side effects').
Če pa vas glede krvavitve skrbi, se nemudoma posvetujte z zdravnikom (glejte poglavje 4
Clopidogrel ratiopharm GmbH 75 mg film-coated tablets
Klopidogrel ratiopharm GmbH 75 mg filmsko obložene tablete
Clopidogrel ratiopharm GmbH 75 mg film-coated tablets clopidogrel
Klopidogrel ratiopharm GmbH 75 mg filmsko obložene tablete klopidogrel
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel ratiopharm GmbH.
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta,
How to take Clopidogrel ratiopharm GmbH
Kako jemati zdravilo Klopidogrel ratiopharm GmbH
Vascular disorders
Bulozen dermatitis
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy.
bolnikov sočasno prejemalo terapijo z antagonisti receptorjev glikoproteinov IIb/IIIa.
Package leaflet: Information for the user Clopidogrel ratiopharm GmbH 75 mg film-coated tablets clopidogrel
Navodilo za uporabo Klopidogrel ratiopharm GmbH 75 mg filmsko obložene tablete klopidogrel
The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e. ST elevation, ST depression or left bundle-branch block).
24 urah po nastopu simptomov, ki bi lahko kazali na miokardni infarkt, z neustreznimi vrednostmi EKG, ki so to potrjevale (elevacija ST spojnice, depresija ST spojnice ali levokračni blok).
How to store Clopidogrel ratiopharm GmbH
Shranjevanje zdravila Klopidogrel ratiopharm GmbH
Gastrointestinal haemorrhage, diarrhoea, abdominal pain, dyspepsia
bolečine v trebuhu, dispepsija
Clopidogrel is extensively metabolised by the liver.
Biotransformacija Klopidogrel se v jetrih izdatno presnovi.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 28 July 2009
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
(očistek kreatinina 5 do 15 ml/min) inhibicija z ADP sprožene agregacije trombocitov manjša (25 %)
Date of first authorisation: 13 April 1999 Date of latest renewal: 25 March 2009
Datum prve odobritve: 13.04.1999 Datum zadnjega podaljšanja: 25.03.2009
EXP For single use only.
EXP Samo za enkratno uporabo.
The changes observed at the low dose of the 13-week studies can be classified as minimal and fully reversible.
Spremembe, ki so jih zasledili po dajanju majhnih odmerkov v 13-tedenskih raziskavah, lahko opredelimo kot minimalne in popolnoma reverzibilne.
Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000
zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do
This can be clarified by an arteriogram.
To lahko odkrijemo z arteriografijo.
However, the treatment is specifically a loco-regional treatment and is not expected to influence survival.
Toda zdravljenje je specifično lokalnoregionalno in ne vpliva na preživetje.
In particular, you should tell your doctor if you are using medicines to lower blood pressure (to treat hypertension).
Zdravniku še zlasti povejte, če jemljete zdravila za znižanje krvnega tlaka (za zdravljenje hipertenzije).
The formulation does not contain a preservative and is for single use only.
Pripravek ne vsebuje konzervansa in je namenjen samo za enkratno uporabo.
Induction of general anaesthesia and subsequent mechanical ventilation should be applied according to standard methods.
Indukcijo splošne anestezije in sledečo mehanično ventilacijo je treba izvajati po standardni metodi.
Systemic adverse reactions include mild constitutional reactions and toxic effects on different organ systems.
Sistemski neželeni učinki vključujejo blage konstitucionalne reakcije in toksične učinke na različne organske sisteme.
If you do, this will not be until at least six weeks after your first ILP.
Če ga bodo, to ne bo prej kot najmanj šest tednov po prvi perfuziji.
- if you are allergic to tasonermin or any of the other ingredients of this medicine (listed in section 6).
- če ste alergični na tasonermin ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
There are no adequate data from the use of tasonermin in pregnant women.
Ni zadostnih podatkov o uporabi tasonermina pri nosečnicah.
Reconstituted solution Chemical and physical in-use stability has been demonstrated for up to 48 hours at 25°C.
Dokazana je bila 48-urna kemična in fizikalna stabilnost med uporabo pri 25 °C.
Treatment with anti-TNFα antibodies is not recommended.
Dajanja protiteles anti-TNFα ne priporočamo.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal
• Redno posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
This technique ensures that Beromun is kept within the affected arm or leg.
Ta tehnika zagotavlja, da zdravilo Beromun ostane znotraj prizadete roke ali noge.
The temperature should then be increased to >39°C (but not exceeding 40°C) in two different sites of measurement in the tumour area.
Nato temperaturo povečamo do > 39 °C (toda ne na več kot 40 °C) na dveh različnih merilnih mestih v predelu tumorja.
The safety and efficacy of Beromun in children under 18 years have not been established.
Pediatrična populacija Varnost in učinkovitost zdravila Beromun pri otrocih, mlajših od 18 let, še nista bili dokazani.
Night sweats
nočno znojenje
Hypercalcaemia > 12 mg/dl (2.99 mmol/l).
Hiperkalcemija > 12 mg/dl (2,99 mmol/l)
Fertility No data on the possible effect of this medicinal product on male and female fertility are available.
Plodnost Podatki o možnih učinkih tega zdravila na plodnost samcev in samic niso na voljo.
Animal studies are insufficient with respect to effects on pregnancy, embryonal development and postnatal development (see section 5.3).
Ni dovolj študij na živalih za oceno vpliva na nosečnost in razvoj zarodka ter postnatalni razvoj (glejte poglavje 5.3).
Further, animals that reject experimental tumours following tasonermin treatment may develop specific immunity for this tumour cell type.
Poleg tega lahko živali, ki zavrnejo eksperimentalno povzročene tumorje po dajanju tasonermina, razvijejo specifično imunost za ta tip tumorskih celic.
Mechanism of action In vivo antitumour activity is probably based on direct and indirect effects:
Protitumorsko delovanje in vivo verjetno temelji na neposrednih in posrednih učinkih:
The circulatory changes included decreased blood pressure and, in some studies, increased heart rate and decreased contractility.
Spremembe krvnega obtoka so bile znižanje krvnega tlaka in, v nekaterih raziskavah, povečana srčna frekvenca in zmanjšana kontraktilnost.
These changes in turn lead to a procoagulant state, resulting in microvascular thrombosis.
Posledica teh sprememb je prokoagulacijsko stanje, ki povzroči mikrovaskularno trombozo.
A second specific and saturable elimination mechanism involving tasonermin receptors seems likely.
Kaže, da je možen tudi drugi, specifični in saturabilni mehanizem izločanja, pri katerem sodelujejo receptorji za tasonermin.
For instructions on administration, see section 4.2.
Za navodila za dajanje glejte poglavje 4.2.
Once opened, the content of a vial should normally be used immediately (see section 6.3).
Vsebino odprte viale je treba takoj uporabiti (glejte poglavje 6.3).
For any information about this medicine, please contact the Marketing Authorisation Holder:
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na imetnika dovoljenja za promet z zdravilom:
The following side effects were observed during treatment with this medicine (grouped by how likely they are to happen).
Med zdravljenjem s tem zdravilom so opazili naslednje neželene učinke (združene po verjetnosti, da se bodo pojavili).
Each pack contains 4 vials.
Eno pakiranje vsebuje 4 viale.
Beromun should only be administered if leakage is less than 10 %.
Zdravilo Beromun smemo dajati samo, če je uhajanje manjše od 10 %.
*tumor necrosis factor alfa-1a (TNFα-1a) produced by recombinant DNA technology in E. coli.
*tumorski nekrotični faktor alfa-1a (TNFα-1a), izdelan s tehnologijo rekombinantne DNK v E. coli.
What Beromun is and what it is used for
Kaj je zdravilo Beromun in za kaj ga uporabljamo
It is important that it does not reach other parts of your body, because this so-called systemic leakage could cause serious side effects on the main organs of the body.
Pomembno je, da ne doseže drugih telesnih delov, ker bi lahko imelo sistemsko uhajanje resne neželene učinke na najpomembnejše telesne organe.
Nerve injury, peripheral neurotoxicity, altered state of consciouness, headache
poškodba živca, nevrotoksičnost, spremenjeno stanje zavesti, glavobol
Thus, the duration of the total perfusion should be 90 minutes.
Tako je skupno trajanje perfuzije 90 minut.
Indirect and direct immunomodulation: Tasonermin has profound effects on cellular components of the immune system.
Posredna in neposredna imunomodulacija: tasonermin ima izrazite učinke na celične sestavine imunskega sistema.
No NOTEL (No Observed Toxic Effect Level) could be established in the preclinical studies with the exception of a 7-day administration of 0.1 µg/kg in monkeys.
Ravni, pri kateri ni zaslediti toksičnega učinka, v predkliničnih raziskavah niso mogli določiti, z izjemo 7-dnevnega dajanja odmerkov po 0,1 μg/kg pri opicah.
If more than 10% of your Beromun dose reaches the main part of your body, your doctor will take similar measures as in the case of overdose.
Če bo v osrednji del telesa ušlo več kot 10 % zdravila Beromun, bo zdravnik izvedel podobne ukrepe kot pri vnosu prevelikega odmerka.
There is no evidence that any of these agents counteracts the pharmacodynamic effects of tasonermin.
Ni podatkov, ki bi kazali, da deluje katero koli od teh zdravil nasprotno farmakodinamičnim učinkom tasonermina.
Precautions to be taken before handling or administering the medicinal product When preparing and handling Beromun solutions, the use of gloves is recommended.
Previdnostni ukrepi, potrebni pred ravnanjem z zdravilom ali dajanjem zdravila Pri pripravi in ravnanju z raztopino Beromun je priporočljiva uporaba rokavic.
The toxicological profile of tasonermin has been investigated in preclinical studies using mice, rats, rabbits, dogs and monkeys.
Toksikološki profil tasonermina so v predkliničnih raziskavah proučevali pri miših, podganah, kuncih, psih in opicah.
Other medicines and Beromun
Druga zdravila in zdravilo Beromun
Contents of the pack and other information What Beromun contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Beromun
After reconstitution in 0.9 % physiological sodium chloride solution the amount is 37.82 mg (1.64 mmol) sodium.
Po rekonstituciji v 0,9 % fiziološki raztopini natrijevega klorida je količina natrija 37,82 mg (1,64 mmol).
Compartment syndrome, myalgia
utesnitveni sindrom, mialgija
If there is any risk of serious side effects, your doctor will immediately transfer you to an intensive care unit to closely monitor you and start adequate treatment.
Če obstaja tveganje za resne neželene učinke, vam bo zdravnik takoj preusmeril na oddelek za intenzivno nego, da pozorno spremlja in uvede ustrezno zdravljenje.
After lower limb perfusion, 3 to 6 litres should be used, and after upper limb perfusion, 1 to 2 litres.
Po perfuziji spodnje okončine moramo uporabiti 3 do 6 litrov, po perfuziji zgornje okončine pa 1 do 2 litra.
It is important to maintain a constant level of anaesthesia in order to prevent large fluctuations in systemic blood pressure, which can affect leakage between systemic circulation and perfusion circuit.
Pomembno je vzdrževati enakomerno globino anestezije, da bi preprečili velika nihanja sistemskega krvnega tlaka, zaradi katerih lahko pride do puščanja med sistemskim obtokom in perfuzijskim krogotokom.
The synthesis capacity of the liver was lowered as indicated by increased liver enzymes.
Zmanjšala se je zmogljivost sinteze v jetrih, kar je pokazalo povečanje jetrnih encimov.
If there is significant systemic leakage of Beromun
Če pride do večjega sistemskega uhajanja zdravila Beromun
What you need to know before you use Beromun Do not use Beromun
Kaj morate vedeti, preden boste uporabili zdravilo Beromun Ne uporabljajte zdravila Beromun
For storage conditions after reconstitution of the medicinal product, see section 6.3.
Za pogoje shranjevanja po rekonstrukciji zdravila glejte poglavje 6.3.
Beromun is contraindicated in pregnancy (see section 4.3).
Zdravilo Beromun je kontraindicirano med nosečnostjo (glejte poglavje 4.3).
Measures should be taken to ensure that the periods of interrupted oxygen supply to the limb are as brief as possible (20 minutes maximum).
Z ustreznimi ukrepi moramo zagotoviti, da bo oskrba okončine s kisikom prekinjena čim krajši čas (največ
It belongs to a class of medicines known as immunostimulants, which help your body's immune system fight cancer cells.
Sodi v skupino zdravil, ki jih imenujemo imunostimulansi, in pomaga imunskemu sistemu v boju proti rakastim celicam.
What Beromun is and what it is used for What you need to know before you use Beromun How to use Beromun
Kaj je zdravilo Beromun in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Beromun Kako uporabljati zdravilo Beromun
Each vial contains 1 mg tasonermin.
Ena viala vsebuje 1 mg tasonermina.
Pharmacotherapeutic group: Other immunostimulants, ATC code: L03AX11
Farmakoterapevtska skupina: drugi imunostimulansi, oznaka ATC: LO3A X11 Mehanizem delovanja
Renal and hepatic function should be closely monitored.
Natančno je treba spremljati ledvično in jetrno funkcijo.
This will occur whilst you are unconscious, under the influence of a general anaesthetic.
Prejeli ju boste, ko boste med splošno anestezijo brez zavesti.
The perfusion circuit (roller pump, oxygenator with integrated reservoir, heat exchanger, connecting tubing) should be prepared prior to surgery and primed with 700 to 800 ml of perfusate, with haematocrit of 0.25 to 0.30.
Perfuzijski sistem (valjčna črpalka, oksigenator z vgrajenim rezervoarjem, toplotni izmenjevalec, povezovalne cevke) je treba pripraviti pred kirurškim posegom in ga napolniti s 700 do 800 ml perfuzijske raztopine, s hematokritom 0,25 do 0,30.
For the prophylaxis of shock, patients should always be maximally hydrated prior to, during and after the perfusion procedure.
Da bi preprečili šok, morajo biti bolniki optimalno hidrirani pred in med perfuzijo ter po njej.
If Beromun dry powder or reconstituted solution should come into contact with the skin or mucous membranes, they should be washed thoroughly with water.
Če prašek zdravila Beromun ali pripravljena raztopina prideta v stik s kožo ali sluznico, jih je treba temeljito umiti z vodo.
Abdominal pain upper, gastritis erosive
bolečina v zgornjem abdomnu, erozivni gastritis
This is to ensure optimal haemodynamic conditions and ensure a high urinary output, especially after the perfusion, to allow for rapid clearance of any residual tasonermin.
S tem zagotovimo optimalne hemodinamične razmere in povečamo izločanje seča, zlasti po perfuziji, da bi se preostanek tasonermina hitro izločil.
In approximately 2% of cases, Beromun may cause tissue damage in your affected arm or leg which is severe enough to require amputation.
Pri približno 2 % primerov lahko povzroči zdravilo Beromun poškodbe tkiva v prizadeti roki ali nogi, ki so tako hude, da je potrebna amputacija.
Washout should be continued until the colour of the perfusate is clear pink, transparent (see section 4.4).
Izpirati je treba, dokler ne postane perfuzijska raztopina čista, rožnata in prozorna; glejte poglavje 4.4).
From a microbiological point of view, the reconstituted product should be used immediately.
Iz mikrobioloških razlogov je treba pripravljeno zdravilo takoj uporabiti.
Several lines of evidence suggest that these immunomodulatory activities are of relevance for the antitumour effects; e.g. the antitumour activities of tasonermin are much less pronounced in immunodeficient animals.
Precej podatkov kaže, da so našteti imunomodulacijski učinki pomembni za protitumorsko delovanje; protitumorsko delovanje tasonermina je na primer veliko manj izrazito pri imunodeficitnih živalih.
It is not known whether tasonermin is excreted in human milk.
Dojenje Ni znano, ali se tasonermin izloča v materino mleko.
These include standard anaesthetic agents, analgesics, antipyretics, intravenous fluids, anticoagulants and vasopressor agents.
To so standardne učinkovine za anestezijo, analgetiki, antipiretiki, intravenske tekočine, antikoagulansi in vazopresorne učinkovine.
The reason for the differential sensitivity of the tumour vasculature (high) versus normal vasculature (low) are currently unknown.
Vzrok za različno občutljivost žilja v tumorju (ki je velika) in normalnega žilja (ki je majhna) še ni znan.